|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBXL2 |
Gene summary for FBXL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBXL2 | Gene ID | 25827 |
| Gene name | F-box and leucine rich repeat protein 2 | |
| Gene Alias | FBL2 | |
| Cytomap | 3p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9UKC9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25827 | FBXL2 | HTA12-15-2 | Human | Pancreas | PDAC | 4.27e-03 | 2.39e-01 | 0.2315 |
| 25827 | FBXL2 | HTA12-23-1 | Human | Pancreas | PDAC | 8.83e-07 | 6.07e-01 | 0.3405 |
| 25827 | FBXL2 | HTA12-25-1 | Human | Pancreas | PDAC | 1.33e-13 | 7.80e-01 | 0.313 |
| 25827 | FBXL2 | HTA12-26-1 | Human | Pancreas | PDAC | 9.18e-12 | 6.05e-01 | 0.3728 |
| 25827 | FBXL2 | HTA12-29-1 | Human | Pancreas | PDAC | 5.31e-31 | 6.57e-01 | 0.3722 |
| 25827 | FBXL2 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 5.36e-07 | 1.66e-01 | -0.2247 |
| 25827 | FBXL2 | 048752_1579-all-cells | Human | Prostate | BPH | 1.63e-35 | 6.40e-01 | 0.1008 |
| 25827 | FBXL2 | 052095_1628-all-cells | Human | Prostate | BPH | 2.94e-13 | 3.75e-01 | 0.1032 |
| 25827 | FBXL2 | 052097_1595-all-cells | Human | Prostate | BPH | 2.04e-38 | 6.25e-01 | 0.0972 |
| 25827 | FBXL2 | 052099_1652-all-cells | Human | Prostate | BPH | 1.00e-36 | 6.25e-01 | 0.1038 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001049814 | Breast | IDC | proteasomal protein catabolic process | 75/1434 | 490/18723 | 5.59e-09 | 4.41e-07 | 75 |
| GO:004217614 | Breast | IDC | regulation of protein catabolic process | 63/1434 | 391/18723 | 1.32e-08 | 9.61e-07 | 63 |
| GO:004316114 | Breast | IDC | proteasome-mediated ubiquitin-dependent protein catabolic process | 57/1434 | 412/18723 | 9.55e-06 | 2.68e-04 | 57 |
| GO:001049824 | Breast | DCIS | proteasomal protein catabolic process | 75/1390 | 490/18723 | 1.44e-09 | 1.40e-07 | 75 |
| GO:004217624 | Breast | DCIS | regulation of protein catabolic process | 62/1390 | 391/18723 | 9.98e-09 | 7.53e-07 | 62 |
| GO:004316124 | Breast | DCIS | proteasome-mediated ubiquitin-dependent protein catabolic process | 57/1390 | 412/18723 | 3.76e-06 | 1.16e-04 | 57 |
| GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
| GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
| GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
| GO:00171574 | Cervix | CC | regulation of exocytosis | 39/2311 | 202/18723 | 2.90e-03 | 1.93e-02 | 39 |
| GO:00068873 | Cervix | CC | exocytosis | 59/2311 | 352/18723 | 8.74e-03 | 4.48e-02 | 59 |
| GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
| GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
| GO:0043161 | Colorectum | AD | proteasome-mediated ubiquitin-dependent protein catabolic process | 141/3918 | 412/18723 | 1.77e-10 | 1.68e-08 | 141 |
| GO:0006887 | Colorectum | AD | exocytosis | 96/3918 | 352/18723 | 2.48e-03 | 1.90e-02 | 96 |
| GO:0017157 | Colorectum | AD | regulation of exocytosis | 59/3918 | 202/18723 | 3.20e-03 | 2.36e-02 | 59 |
| GO:0099003 | Colorectum | AD | vesicle-mediated transport in synapse | 57/3918 | 200/18723 | 6.53e-03 | 4.06e-02 | 57 |
| GO:00421762 | Colorectum | MSS | regulation of protein catabolic process | 145/3467 | 391/18723 | 2.03e-18 | 1.17e-15 | 145 |
| GO:00104982 | Colorectum | MSS | proteasomal protein catabolic process | 157/3467 | 490/18723 | 2.39e-13 | 5.25e-11 | 157 |
| GO:00431612 | Colorectum | MSS | proteasome-mediated ubiquitin-dependent protein catabolic process | 127/3467 | 412/18723 | 7.70e-10 | 6.32e-08 | 127 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBXL2 | SNV | Missense_Mutation | rs756929713 | c.335A>G | p.Asn112Ser | p.N112S | Q9UKC9 | protein_coding | tolerated(0.65) | benign(0.007) | TCGA-AC-A3TN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| FBXL2 | SNV | Missense_Mutation | c.248T>G | p.Leu83Arg | p.L83R | Q9UKC9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EW-A1P3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| FBXL2 | insertion | In_Frame_Ins | novel | c.1120_1121insGGCATTCTTGCTGTGTCATCCCATTGCAGAAGGGCA | p.Tyr374delinsTrpHisSerCysCysValIleProLeuGlnLysGlyAsn | p.Y374delinsWHSCCVIPLQKGN | Q9UKC9 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| FBXL2 | SNV | Missense_Mutation | rs370862715 | c.229N>A | p.Gly77Ser | p.G77S | Q9UKC9 | protein_coding | deleterious(0.01) | benign(0.406) | TCGA-EK-A2RE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FBXL2 | SNV | Missense_Mutation | c.101G>A | p.Arg34Gln | p.R34Q | Q9UKC9 | protein_coding | deleterious(0.04) | probably_damaging(0.979) | TCGA-AA-3976-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR | |
| FBXL2 | SNV | Missense_Mutation | c.218N>T | p.Ser73Leu | p.S73L | Q9UKC9 | protein_coding | deleterious(0) | possibly_damaging(0.781) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| FBXL2 | SNV | Missense_Mutation | rs774933477 | c.659N>A | p.Arg220His | p.R220H | Q9UKC9 | protein_coding | tolerated(0.37) | benign(0) | TCGA-DM-A1D4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| FBXL2 | SNV | Missense_Mutation | c.139N>A | p.Leu47Met | p.L47M | Q9UKC9 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FBXL2 | SNV | Missense_Mutation | rs151236863 | c.1030N>T | p.Arg344Trp | p.R344W | Q9UKC9 | protein_coding | deleterious(0.01) | benign(0.339) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FBXL2 | SNV | Missense_Mutation | c.1192G>A | p.Ala398Thr | p.A398T | Q9UKC9 | protein_coding | tolerated(0.05) | probably_damaging(0.995) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |